| Dr Samina Altaf Syed-naqvi, MD | |
|
415 Avenel St # B, Avenel, NJ 07001-1147 | |
| (732) 634-4300 | |
| (732) 634-4302 |
| Full Name | Dr Samina Altaf Syed-naqvi |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 38 Years |
| Location | 415 Avenel St # B, Avenel, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306998752 | NPI | - | NPPES |
| 0150452 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA07505700 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Institute For Hypertension And Kidney Diseases, P.c. | 8820189129 | 6 |
News Archive
Analyzing a puzzling multisystem disorder in three children, genetic experts have identified a new syndrome, shedding light on key biological processes during human development. The research also provides important information to help caregivers manage the disorder, and may offer clues to eventually treating it.
The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.
Integra LifeSciences Holdings Corporation today reported its financial results for the first quarter ending March 31, 2010. Total revenues for the first quarter were $172.7 million, reflecting an increase of $11.7 million, or 7%, over the first quarter of 2009. Excluding the impact of currency exchange rates, revenues increased 6% over the first quarter of 2009.
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, called NitroSynapsin, largely corrected electrical, behavioral and brain abnormalities in the mice.
Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.
› Verified 2 days ago
| Entity Name | Institute For Hypertension And Kidney Diseases, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053441840 PECOS PAC ID: 8820189129 Enrollment ID: O20070801000013 |
News Archive
Analyzing a puzzling multisystem disorder in three children, genetic experts have identified a new syndrome, shedding light on key biological processes during human development. The research also provides important information to help caregivers manage the disorder, and may offer clues to eventually treating it.
The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.
Integra LifeSciences Holdings Corporation today reported its financial results for the first quarter ending March 31, 2010. Total revenues for the first quarter were $172.7 million, reflecting an increase of $11.7 million, or 7%, over the first quarter of 2009. Excluding the impact of currency exchange rates, revenues increased 6% over the first quarter of 2009.
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, called NitroSynapsin, largely corrected electrical, behavioral and brain abnormalities in the mice.
Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.
› Verified 2 days ago
| Entity Name | Rwjbh Primary Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265037501 PECOS PAC ID: 0749699346 Enrollment ID: O20210512000720 |
News Archive
Analyzing a puzzling multisystem disorder in three children, genetic experts have identified a new syndrome, shedding light on key biological processes during human development. The research also provides important information to help caregivers manage the disorder, and may offer clues to eventually treating it.
The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.
Integra LifeSciences Holdings Corporation today reported its financial results for the first quarter ending March 31, 2010. Total revenues for the first quarter were $172.7 million, reflecting an increase of $11.7 million, or 7%, over the first quarter of 2009. Excluding the impact of currency exchange rates, revenues increased 6% over the first quarter of 2009.
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, called NitroSynapsin, largely corrected electrical, behavioral and brain abnormalities in the mice.
Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samina Altaf Syed-naqvi, MD 415 Avenel St Ste B, Avenel, NJ 07001-1147 Ph: (732) 634-4300 | Dr Samina Altaf Syed-naqvi, MD 415 Avenel St # B, Avenel, NJ 07001-1147 Ph: (732) 634-4300 |
News Archive
Analyzing a puzzling multisystem disorder in three children, genetic experts have identified a new syndrome, shedding light on key biological processes during human development. The research also provides important information to help caregivers manage the disorder, and may offer clues to eventually treating it.
The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.
Integra LifeSciences Holdings Corporation today reported its financial results for the first quarter ending March 31, 2010. Total revenues for the first quarter were $172.7 million, reflecting an increase of $11.7 million, or 7%, over the first quarter of 2009. Excluding the impact of currency exchange rates, revenues increased 6% over the first quarter of 2009.
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, called NitroSynapsin, largely corrected electrical, behavioral and brain abnormalities in the mice.
Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.
› Verified 2 days ago
Jozsef Samuel Duhl, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1030 St Georges Avenue, Suite 103a, Avenel, NJ 07001 Phone: 732-596-0155 Fax: 732-596-0158 | |
Dr. Bernard James Kulper, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1030 Saint Georges Ave, Suite 307, Avenel, NJ 07001 Phone: 732-750-1200 Fax: 732-602-4044 | |
Dr. Andras Peter, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1030 Saint Georges Ave, Suite 103a, Avenel, NJ 07001 Phone: 732-596-1666 Fax: 732-596-0158 | |
Dr. Mark Skrzypczak, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1030 Saint Georges Ave Ste 302, Avenel, NJ 07001 Phone: 732-750-1200 Fax: 732-669-9899 | |
David L Romano, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1030 Saint Georges Ave, Ste 201, Avenel, NJ 07001 Phone: 732-602-0244 Fax: 732-602-2577 | |
Alexander M Swan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1030 Saint Georges Ave Ste Ll-1, Avenel, NJ 07001 Phone: 732-750-5555 Fax: 732-750-5550 |